Research Papers:

PATZ1 expression correlates positively with BAX and negatively with BCL6 and survival in human diffuse large B cell lymphomas

Renato Franco, Giosuè Scognamiglio, Elena Valentino, Michela Vitiello, Antonio Luciano, Giuseppe Palma, Claudio Arra, Elvira La Mantia, Luigi Panico, Valentina Tenneriello, Antonello Pinto, Ferdinando Frigeri, Gaetana Capobianco, Gerardo Botti, Laura Cerchia, Annarosaria De Chiara and Monica Fedele _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:59158-59172. https://doi.org/10.18632/oncotarget.10993

Metrics: PDF 1791 views  |   HTML 2297 views  |   ?  


Renato Franco1,2,*, Giosuè Scognamiglio1,*, Elena Valentino1, Michela Vitiello3, Antonio Luciano4, Giuseppe Palma4, Claudio Arra4, Elvira La Mantia1, Luigi Panico5, Valentina Tenneriello5, Antonello Pinto6, Ferdinando Frigeri6, Gaetana Capobianco6, Gerardo Botti1, Laura Cerchia3, Annarosaria De Chiara1, Monica Fedele3

1Surgical Pathology Unit, National Cancer Institute ‘Fondazione Giovanni Pascale’, IRCCS, Naples, Italy

2Pathology Unit, Second University of Naples, Naples, Italy

3Institute of Experimental Endocrinology and Oncology (IEOS), National Research Council (CNR), Naples, Italy

4Animal Facility, National Cancer Institute ‘Fondazione Giovanni Pascale’, IRCCS, Naples, Italy

5Pathology Unit, Hospital ‘S.G. Moscati’, Avellino, Italy

6Haematology-Oncology and Stem Cell Transplantation Unit, Department of Hematology, National Cancer Institute, Fondazione ‘G. Pascale’, IRCCS, Naples, Italy

*These authors share co-first authorship

Correspondence to:

Monica Fedele, email: [email protected], [email protected]

Renato Franco, email: [email protected], [email protected]

Keywords: non-Hodgkin lymphomas, prognostic marker, PATZ1, tissue-microarray, DLBCL

Received: January 16, 2016     Accepted: July 18, 2016     Published: August 01, 2016


Non-Hodgkin lymphomas (NHLs) include a heterogeneous group of diseases, which differ in both cellular origin and clinical behavior. Among the aggressive malignancies of this group, the diffuse large B-cell lymphomas (DLBCLs) are the most frequently observed. They are themselves clinically and molecularly heterogeneous and have been further sub-divided in three sub-types according to different cell of origin, mechanisms of oncogenesis and clinical outcome. Among them, the germinal center B-cell-like (GCB) derives from the germinal center and expresses the BCL6 oncogene. We have previously shown that Patz1-knockout mice develop B-cell neoplasias, suggesting a tumor suppressor role for PATZ1 in human NHLs. Here, by immunohistochemical analysis of a tissue-microarray including 170 NHLs, we found that PATZ1 nuclear expression is down-regulated in follicular lymphomas and DLBCLs. Moreover, consistent with our previous results showing a PATZ1-dependent regulation of BCL6 and BAX transcription, we show that low PATZ1 nuclear expression significantly correlates with high BCL6 expression, mainly in DLBCLs, and with low BAX expression, also considering separately follicular lymphomas and DLBCLs. Finally, by analyzing overall and progression-free survival in DLBCL patients that underwent rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy, low levels of PATZ1 were significantly associated to a worst outcome and demonstrated an independent prognostic factor in multivariate analysis, including known prognostic factors of DLBCL, IPI score and cell of origin (GCB/non-GCB). Therefore, we propose PATZ1 as a new prognostic marker of DLBCLs, which may act as a tumor suppressor by enhancing apoptosis through inhibiting and enhancing transcription of BCL6 and BAX, respectively.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10993